To participate in retail category, one can go for around 2,200 number of shares.
The theoretical acceptance ration in this case would turn out to be around 19%.
However 100% of application is not possible in buyback.
Assuming 3 different scenario for the expected application of buyback that is 50%, 70% and 90%, the tender ratio would turn out to be 37%, 26% and 21% respectively.
After sales price of buyback:
Assuming 3 different scenario of post buyback share price, we would make following return presented in the image from the NPTC Buyback case study.
Price expectation is presented in our article which is in next thread.
6 out of 9 scenario are in favour of buyback.
While 2 scenario will miss opportunity cost.
Assuming our normal case 70% expected application of buyback and the base case price of Rs 80, one would make 4% return in 2-3 months, making around 24% annually.
We are not a SEBI registered investment advisor. Please consult your advisor before investing.
We remain invested on the basis of our buyback framework.
Presented all our buyback plays over this forum in Value Pickr. Would be glad to discuss with everyone over this forum so that everyone learn from each other's experience
-It will take a year or two to reach at Pre-Covid Levels
-They are trying to get more international business
-Planning to expand their Bangladesh business
-There was some loss in average selling price this quarter
-They are 2nd largest Luggage company in the World
Strategy:
-E-comm sales is 27% and this is going to be their material channel ahead
-It will continue to be in this range
-Amazon and Flipkart would be like their departmental/retail stores and simultaneously they would be having their exclusive stores also
ANFD:
• In manufacturing ever plant require to convert solid into liquid by filtration. ANFD does filtration, washing of impurities, drying and is automated.
• Complied with CGMP
• Can be useful even in hazardous chemical
• Focus remain of launching quality product and annual innovation in products.
• Company has Formidable player in Glass line market.
• Manufactured 250 products for even single order and have already fulfilled many diverse range of order.
Business Updates:
• GDS and CMS segment both have contribute well.
• Unit 3 will be commercialized in 2 quarter of FY 2021
• Growth was led by Levofloxacin and Levetiracetam
• CMS business was the key driver for growth. Good progress from CMS
CAPEX:
• Expectation of 90cr this year and 60-70cr is done
• No further updates on CAPEX but there will be need
CMS:
• Growth driven by increase in commercial projects which done well. Baseline project done well
• CMS business could be volatile. Overall growth is positive
• EBIDTA margins improved, significant growth from COVID.
• Non - Covid business is back to pre-covid levels.
COVID test:
• RTPCR tests in Q2 ~ 2.7 Lac
• Antibody tests reported in Q2
• Pathology Volumes increased by 83% in Q2
• Added manpower in the operational end
• In Q2 almost 40% of the business is from Covid
• As the industry open up, there can be more demand of antibody test.
• There would be no complexity in serving the operational aspect of working with open up in the economy